Keyphrases
Doxorubicin
100%
Antiangiogenic Activity
100%
Apoptotic Effect
100%
Soft Tissue Sarcoma
100%
Local Growth
66%
Angiogenesis
33%
Metastatic Growth
33%
Tumor Cell Proliferation
33%
TRAIL Receptors
33%
Human Soft Tissue
33%
Clinical Trials
16%
Quantitative PCR
16%
Apoptosis
16%
Novel Therapeutics
16%
Interleukin-8
16%
Magnetic Resonance Imaging
16%
Chemotherapy
16%
Treatment Effect
16%
Growth Inhibition
16%
Tumor
16%
Systemic Approach
16%
Induced Gene Expression
16%
Gene Expression Changes
16%
Wild-type p53
16%
Metastasis
16%
Xenograft
16%
Complex Karyotype
16%
Severe Combined Immunodeficient Mice
16%
Receptor Expression
16%
Angiogenic
16%
Overall Survival
16%
Bioluminescence
16%
Lung Metastasis
16%
Host Survival
16%
CXCL10
16%
Antiangiogenic Factors
16%
Microvessel Density
16%
P53-independent
16%
Angiogenic Factors
16%
Mutated p53
16%
Mouse Xenograft Model
16%
Proliferation Apoptosis
16%
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling
16%
Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)
16%
Leiomyosarcoma
16%
Fibrosarcoma
16%
Low-dose Chemotherapy
16%
Combined Therapy
16%
HT1080
16%
Medicine and Dentistry
Doxorubicin
100%
Antiangiogenic Activity
100%
Soft Tissue Sarcoma
100%
Protein P53
50%
Xenograft
33%
Cell Proliferation
33%
Tumor Cell
33%
Programmed Cell Death
33%
Angiogenesis
33%
In Vitro
16%
Treatment Effect
16%
Low Drug Dose
16%
Gene Expression
16%
Neoplasm
16%
Magnetic Resonance Imaging
16%
Clinical Trial
16%
Real-Time Polymerase Chain Reaction
16%
Metastatic Carcinoma
16%
Growth Inhibition
16%
Karyotype
16%
SCID Mouse
16%
Receptor Expression
16%
Lung Metastasis
16%
Cytokine
16%
Antiangiogenic
16%
Overall Survival
16%
Microvessel
16%
TUNEL Assay
16%
DNA Nucleotidylexotransferase
16%
Interleukin 8
16%
Leiomyosarcoma
16%
Angiogenic Factor
16%
Fibrosarcoma
16%
Combined Therapy
16%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
16%
Low-Dose Chemotherapy
16%
HT1080
16%
Death Receptor 5
16%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand Receptor
16%
Death Receptor 4
16%
Bioluminescence
16%
Neuroscience
In Vivo
100%
Doxorubicin
100%
P53
75%
Cell Proliferation
50%
Angiogenesis
50%
Programmed Cell Death
50%
Gene Expression
25%
Magnetic Resonance Imaging
25%
Staining Technique
25%
In Vitro
25%
Karyotype
25%
Real-Time Polymerase Chain Reaction
25%
Receptor Expression
25%
TUNEL Assay
25%
DNA Nucleotidylexotransferase
25%
Angiogenic Factor
25%
Microvessel
25%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
25%
CXCL10
25%
Death Receptor 5
25%
Death Receptor 4
25%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand Receptor
25%
Low-Dose Chemotherapy
25%
Interleukin 8
25%
Bioluminescence
25%
Pharmacology, Toxicology and Pharmaceutical Science
Doxorubicin
100%
Antiangiogenic
100%
Soft Tissue Sarcoma
100%
Neoplasm
50%
Protein P53
50%
Chemotherapy
33%
Clinical Trial
16%
Cytokine
16%
Lung Metastasis
16%
Overall Survival
16%
Angiogenic Factor
16%
SCID Mouse
16%
Interleukin 8
16%
DNA Nucleotidylexotransferase
16%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
16%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand Receptor
16%
Leiomyosarcoma
16%
Fibrosarcoma
16%
Death Receptor 4
16%
Death Receptor 5
16%
Biochemistry, Genetics and Molecular Biology
Antiangiogenic Activity
100%
TRAIL
100%
Doxorubicin
100%
P53
37%
Programmed Cell Death
37%
Angiogenesis
25%
Cell Proliferation
25%
Low Drug Dose
25%
Gene Expression
12%
Wild Type
12%
Karyotype
12%
Real-Time Polymerase Chain Reaction
12%
Cytokine
12%
Clinical Trial
12%
Growth Inhibition
12%
Interleukin 8
12%
Tumor Necrosis Factor
12%
Overall Survival
12%
Terminal Deoxynucleotidyl Transferase
12%
TUNEL Assay
12%
CXCL10
12%
SCID Mouse
12%
Magnetic Resonance Imaging
12%
Bioluminescence
12%